Community-acquired pneumonia in Shanghai, China: microbial etiology and implications for empirical therapy in a prospective study of 389 patients

被引:58
作者
Huang, H. H. [1 ]
Zhang, Y. Y.
Xiu, Q. Y.
Zhou, X.
Huang, S. G.
Lu, Q.
Wang, D. M.
Wang, F.
机构
[1] Fudan Univ, Huashan Hosp, Inst Antibiot, Shanghai 200040, Peoples R China
[2] Changzheng Hosp, Shanghai 200003, Peoples R China
[3] First Peoples Hosp, Shanghai 200080, Peoples R China
[4] Ruijin Hosp, Shanghai 200025, Peoples R China
[5] Shanghai Childrens Hosp, Shanghai 200040, Peoples R China
[6] Fudan Univ, Childrens Hosp, Shanghai 200032, Peoples R China
关键词
D O I
10.1007/s10096-006-0146-7
中图分类号
R51 [传染病];
学科分类号
100401 [流行病与卫生统计学];
摘要
The aim of this multicenter study was to identify the causative pathogens of community-acquired pneumonia (CAP) in Shanghai, China, and to determine their susceptibility to antimicrobial agents. Pathogens obtained from 389 patients with documented CAP during 2001-2003 were identified by multiple diagnostic tools that included bacterial culture, polymerase chain reaction (PCR), and specific immunological assays. Susceptibility of the bacterial isolates was tested by the broth microdilution method. A specific pathogen was identified in 39.8% (155/389) of the patients: Haemophilus influenzae (n=80), Klebsiella spp. (n=15), Streptococcus pneumoniae (n=12), Staphylococcus aureus (n=6), Moraxella catarrhalis (n=1), other gram-negative organisms (n=9), and atypical pathogens that comprised Mycoplasma pneumoniae (n=42), Chlamydia pneumoniae (n=17), and Legionella pneumophila (n=2). Most H. influenzae isolates were susceptible to ampicillin (88.3%), and all were susceptible to macrolides. Of the S. pneumoniae isolates, 75% (9/12) were susceptible to penicillin, while 25% (3/12) were intermediately susceptible. H. influenzae and atypical pathogens are among the most important pathogens of CAP. Ampicillin, cephalosporins, and the newer fluoroquinolones can be used as empirical therapy for CAP in the Shanghai area. The efficacy of monotherapy with newer macrolides for CAP caused by S. pneumoniae requires further evaluation.
引用
收藏
页码:369 / 374
页数:6
相关论文
共 31 条
[1]
Problems and perspectives in the treatment of respiratory infections caused by atypical pathogens [J].
Allegra, L ;
Blasi, F .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2001, 14 (01) :21-27
[2]
[Anonymous], 2003, NCCLS Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, V6th
[3]
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis:: report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States [J].
Biedenbach, DJ ;
Jones, RN ;
Pfaller, MA .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2001, 39 (04) :245-250
[4]
CHEN MJ, 1998, CLIN J INFECT DIS, V16, P238
[5]
Legionella pneumophila serogroup 1 antibody kinetics in patients with Legionnaires' disease:: Implications for serological diagnosis [J].
Darelid, J ;
Löfgren, S ;
Malmvall, BE ;
Olinder-Nielsen, AM ;
Briheim, G ;
Hallander, H .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2003, 35 (01) :15-20
[6]
Laboratory diagnosis of Mycoplasma pneumoniae infection [J].
Daxboeck, F ;
Krause, R ;
Wenisch, C .
CLINICAL MICROBIOLOGY AND INFECTION, 2003, 9 (04) :263-273
[7]
Standardizing Chlamydia pneumoniae assays:: Recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada) [J].
Dowell, SF ;
Peeling, RW ;
Boman, J ;
Carlone, GM ;
Fields, BS ;
Guarner, J ;
Hammerschlag, MR ;
Jackson, LA ;
Kuo, CC ;
Maass, M ;
Messmer, TO ;
Talkington, DF ;
Tondella, ML ;
Zaki, SR ;
Bandea, C ;
Black, C ;
O'Conner, S ;
Papp, J ;
Perilla, MJ ;
Schuchat, A ;
Stevens, V ;
Van Beneden, CA ;
Zell, ER ;
Cohen, C ;
Campbell, LA ;
Wwang, SP ;
Grayston, JT ;
Deal, CD ;
Gaydos, C ;
Schindler, L ;
Taylor, CE ;
Mahony, J ;
Fong, IW ;
Leinonen, M ;
Saikku, P ;
Maas, M ;
Ossewaarde, JM ;
Persson, K ;
Boman, J ;
Apfalter, P .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (04) :492-502
[8]
Community acquired pneumonia - a prospective UK study [J].
Drummond, P ;
Clark, J ;
Wheeler, J ;
Galloway, A ;
Freeman, R ;
Cant, A .
ARCHIVES OF DISEASE IN CHILDHOOD, 2000, 83 (05) :408-412
[9]
In vitro activity of gatifloxacin, compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species [J].
Dubois, J ;
St -Pierre, C .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1999, 33 (04) :261-265
[10]
Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia [J].
File, TM ;
Garau, J ;
Blasi, F ;
Chidiac, C ;
Klugman, K ;
Lode, H ;
Lonks, JR ;
Mandell, L ;
Ramirez, J ;
Yu, V .
CHEST, 2004, 125 (05) :1888-1901